Navigation Links
Promising Results in Treating Facial Bruising From Injectables
Date:9/26/2007

esthetic treatments nationwide last year. According to the American Society for Aesthetic Plastic Surgery, more than 5 million women had injectable cosmetic treatments last year. Bruising is a common temporary side effect.

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)... Additional Data Presentation Shows Encouraging ...ving Patients with Predominantly Complex Lesions, ...day announced that an,interim analysis of 12-month... show good safety and efficacy in the real-world u..., Presented by Professor Robbert de Winter, M.D.,...
(Date:10/13/2008)... New Analysis of SPIRIT II and SPIRIT III Data Co...r Risk of Experiencing Death, a Heart Attack or a ... Two Years, WASHINGTON, Oct. 13 /PRNewswire-First... Abbott,s SPIRIT II and SPIRIT III randomized clin...rolimus Eluting Coronary Stent,System continues to...
(Date:10/13/2008)... FirstVue(TM) HBSAG Test Found to Have Higher Sen...Tests and FirstVue(TM) ,...and was the preferred ...on, CORAL SPRINGS, Fla., Oct. 13 /-...keting leader in rapid diagnostic test kits, today...he Walter Reed Army,Institute of Research of the F...
(Date:10/13/2008)... HOPKINTON, Mass., Oct. 13 /- Face...f 6 month follow-up on 20 patients from its US,IDE...Oswestry Disability,Index (ODI) scores, and an 80%...omatic leg pain. Geoff Pardo, President & CEO for ...these early results, which thus far not,only demon...
Breaking Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 5Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Weight gain related to postmenopausal breast cancer risk 4302 1Weight gain related to postmenopausal breast cancer risk 4302 2Fighting obesity may be as easy as ATP says UH researcher 4299 1Fighting obesity may be as easy as ATP says UH researcher 4299 2Fighting obesity may be as easy as ATP says UH researcher 4299 3Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 1Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 2Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 3This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 1This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 2This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 3This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 4
...ESS WIRE)--Apr 16, 2007 - Arsenic, a naturally,occ...unds for over,2,000 years, and even now remains a ...harmacopeia., Today, due in measure to the efforts...uel Waxman Cancer Research Foundation,s,(SWCRF) "I...being,utilized in therapy for the treatment of cer...
...SINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics,... class of,nucleic-acid drugs based on DNA interfer...y therapeutic candidate, PNT2258,has successfully...graft mice for a number of human cancers - includi...s Lymphoma., Dr. Richard D. Gill, President and CE...
Other Medicine Technology:Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...t patients who develop Parkinson's disease in yout...cohol// abuse may be more likely to develop pathol...ed to treat their condition. Behaviors associated...sive shopping, hypersexuality, binge eating and pa...
... sclerosis (MS) for 10 years and have few of the d...ey// have “benign MS” and that their symptoms will... people with MS. A new study shows that unfortunat...0 years, the disease had progressed in nearly half...
...ge for colorectal cancer screening has increased, ...ng// practices. According to a report published re..., sex, age, education and income levels. Colorec...ncer affecting men and women in the United States ...
... a powerful two-gene test that can distinguish bet... cancers that require radically different courses ... in the online Early Edition of the Proceedings of...iences. "This simple and accurate test has the po...
Other Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: